sorafenib has been researched along with rtki cpd in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (rtki cpd) | Trials (rtki cpd) | Recent Studies (post-2010) (rtki cpd) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 41 | 0 | 21 |
| Protein | Taxonomy | sorafenib (IC50) | rtki cpd (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.125 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1152 | |
| Fructose-1,6-bisphosphatase 1 | Homo sapiens (human) | 1.3 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 2.7 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.56 | |
| Tyrosine-protein kinase ABL2 | Homo sapiens (human) | 0.125 | |
| Epidermal growth factor receptor | Mus musculus (house mouse) | 0.1 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.56 | |
| MAP kinase-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | 0.53 | |
| Histamine H3 receptor | Rattus norvegicus (Norway rat) | 1.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
1 review(s) available for sorafenib and rtki cpd
| Article | Year |
|---|---|
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |